The Lead Episode 155: A Discussion of A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD)-The Lead Episode 155 Speaker Information

The Lead Episode 155 Speaker Information

Pdf Summary

This document is a title and speaker information slide for a discussion of the AVANT GUARD study, a prospective, randomized, multicenter global trial comparing pulsed field ablation with anti-arrhythmic drug therapy as a first-line treatment for persistent atrial fibrillation. The session is hosted by Christopher C. Cheung, MD, MPH, FHRS of Sunnybrook Health Sciences Centre, University of Toronto.<br /><br />The contributors listed are Paul C. Zei, MD, PhD, FHRS from Mass General Brigham and Edward P. Gerstenfeld, MD, MS, FHRS from the University of California, San Francisco. The slide also provides disclosure statements for the host and one contributor, noting various honoraria, consulting fees, research support, and professional roles with multiple medical device and healthcare companies.<br /><br />Overall, the content serves as an introductory and disclosure page rather than presenting study results or detailed scientific findings.

Keywords

AVANT GUARD study

pulsed field ablation

anti-arrhythmic drug therapy

persistent atrial fibrillation

randomized multicenter trial

first-line treatment

Christopher C. Cheung

Paul C. Zei

Edward P. Gerstenfeld

disclosure statements